Dual targeting of HER2 and VEGFR in ovarian cancer

Ovarian cancer is a common cancer of the female reproductive system, for which effective targeted therapies remain insufficient. In this study, researchers used clinical models of ovarian cancer to assess the therapeutic efficacy of RC48, a HER2-targeted antibody-drug conjugate. It was used alone or in combination with the anti-VEGFR drug cediranib maleate in the treatment of advanced ovarian cancer. Results showed that RC48 alone effectively inhibited the growth of HER2+ tumor cells in the clinical models used. When RC48 was combined with cediranib maleate, the researchers observed synergistic tumor inhibition.